Ceftobiprole: First cephalosporin with activity against methicillin-resistant Staphylococcus aureus

Pharmacotherapy

Volumn 29, Issue 5, 2009, Pages 511-525

  Vidaillac, Céline ^a   Rybak, Michael J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BAL9141; Ceftobiprole; Complicated skin and skin structure infections; CSSSI; Methicillin resistant Staphylococcus aureus; MRSA

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; PENICILLIN BINDING PROTEIN 2X; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL CELL WALL; BACTEROIDES FRAGILIS; BINDING AFFINITY; BRAIN INFECTION; CENTRAL NERVOUS SYSTEM DISEASE; CLOSTRIDIUM; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC FOOT; DIARRHEA; DISEASE MODEL; DRUG APPROVAL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INCOMPATIBILITY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TRANSPORT; DRUG WITHDRAWAL; DYSGEUSIA; ENDOCARDITIS; ENTEROBACTER; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; ENZYME DEGRADATION; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; HYDROLYSIS; HYPERSENSITIVITY; HYPOKALEMIA; HYPONATREMIA; INJECTION SITE REACTION; INSOMNIA; KIDNEY DISEASE; KLEBSIELLA PNEUMONIAE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOMYELITIS; PERITONITIS; PLASMA HALF LIFE; PNEUMONIA; POSTANTIBIOTIC EFFECT; PREGNANCY; PROTEIN SYNTHESIS; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; REVIEW; SEPTICEMIA; SINGLE DRUG DOSE; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; VOMITING;

ANIMALS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL SKIN INFECTIONS; TIME FACTORS;

EID: 66249125680     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.5.511     Document Type: Review

References (76)

1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(suppl 5): S344-9.
2. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillinresistant Staphylococcus aureus in intensive care units in U.S. hospitals, 1992-2003. Clin Infect Dis 2006;42:389-91.
3. Szekely E, Lorinczi L, Bilca D, Fodor E, Soki J, Sabau M. Incidence, antibiotic resistance and clonal relations of MRSA strains isolated from a Romanian university hospital. Acta Microbiol Immunol Hung 2008;55:1-13.
4. Cowcroft N, Duckworth G, Griffiths C, Lamagni TL, Rooney C. Deaths involving MRSA: England and Wales, 1993-2006. Health Stat Q 2008;37:57-62.
5. Stapleton PD, Taylor PW. Methicillin resistance in Staphylococcus aureus: mechanisms and modulation. Sci Prog 2002;85:57-72.
6. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46(suppl 5):S360-7.
7. Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MG, Then RL. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillinresistant staphylococci. Antimicrob Agents Chemother 2001;45:825-36.
8. Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004;48:2570-5.
9. El-Shaboury SR, Saleh GA, Mohamed FA, Rageh AH. Analysis of cephalosporin antibiotics. J Pharm Biomed Anal 2007; 45:1-19.
10. Lovering A, Danel F, Page M, Strynadka NJ. Mechanism of action of ceftobiprole: structural basis for anti-MRSA activity. Presented as a poster at the 16th European congress of clinical microbiology and infectious diseases, Nice, France, April 1-4, 2006.
11. Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007;16:419-29.
12. Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 2007;60:594-8.
13. Kosowska K, Hoellman DB, Lin G, et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005;49:1932-42.
14. Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K. Binding of ceftobiprole and comparators to the penicillinbinding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 2007;51:2621-4.
15. Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother 2008;61:595-602.
16. Janssen-Ortho, Inc. Zeftera (ceftobiprole medocaril) package insert. Toronto, Ontario, Canada; 2008.
17. Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K. In vitro activity of ceftobiprole against pathogens from two phase 3 complicated skin and skin structure infection clinical trials. Antimicrob Agents Chemother 2008;52:3418-23.
18. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY antimicrobial surveillance program (2005-2006). Diagn Microbiol Infect Dis 2008;61:86-95.
19. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002;50:915-32.
20. Issa NC, Rouse MS, Piper KE, Wilson WR, Steckelberg JM, Patel R. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn Microbiol Infect Dis 2004;48:73-5.
21. Zbinden R, Punter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrob Agents Chemother 2002;46:871-4.
22. Ednie L, Shapiro S, Appelbaum PC. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diagn Microbiol Infect Dis 2007;58:133-6.
23. Wootton M, Bowker KE, Holt HA, MacGowan AP. BAL9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J Antimicrob Chemother 2002;49:535-9.
24. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broadspectrum cephalosporin. Antimicrob Agents Chemother 2005;49:4210-19.
25. Lin G, Appelbaum PC. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Diagn Microbiol Infect Dis 2008;60:233-5.
26. Lemaire S, Van Bambeke F, Glupczynski Y, Tulkens PM. Intraphagocytic activities of ceftobiprole and conventional cephalosporins against methicillin-sensitive (MSSA) and methicillin-resistant S. aureus (MRSA). Presented as a poster at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
27. Denis O, Deplano A, Nonhoff C, et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother 2006;50:2680-5.
28. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 2007;58:363-5.
29. Deshpande L, Rhomberg PR, Fritsche TR, et al. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary gram-positive and gram-negative isolates. Diagn Microbiol Infect Dis 2004;50:73-5.
30. von Eiff C, Friedrich AW, Becker K, Peters G. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob Agents Chemother 2005;49:4372-4.
31. Ligozzi M, Pittaluga F, Fontana R. Modification of penicillinbinding protein 5 associated with high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1996;40:354-7.
32. Queenan AM, Shang W, Kania M, Page MG, Bush K. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob Agents Chemother 2007;51: 3089-95.
33. Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU study. J Antimicrob Chemother 2008;62:206-8.
34. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006;50:3959-62.
35. Katayama Y, Zhang HZ, Chambers HF. PBP2a mutations producing very-high-level resistance to β-lactams. Antimicrob Agents Chemother 2004;48:453-9.
36. Vaudaux P, Gjinovci A, Bento M, Li D, Schrenzel J, Lew DP. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:3789-93.
37. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:884-8.
38. Azoulay-Dupuis E, Bedos JP, Mohler J, Schmitt-Hoffmann A, Schleimer M, Shapiro S. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother 2004;48:1105-11.
39. Clark C, Bogdanovic T, Ednie LM, Appelbaum PC. Low propensity of ceftobiprole to select for resistant mutants of H. influenzae and M. catarrhalis. Presented as a poster at the 45th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, December 16-19, 2005.
40. Queenan AM, Bush K. Ceftobiprole: effect on AmpC β-lactamase induction and resistance frequency in gram-negative bacteria. Presented as a poster at the 47th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, December 16-19, 2007.
41. Dzidic S, Suskovic J, Kos B. Antibiotic resistance mechanisms in bacteria: biochemical and genetic aspects. Food Technol Biotechnol 2008;46:11-21.
42. Jones ME. In vitro profile of a new β-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007;13(suppl 2):17-24.
43. Davies TA, Shang W, Bush K. Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP1a, PBP2b, and PBP2x. Antimicrob Agents Chemother 2006;50:2530-2.
44. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2089-96.
45. Baum EZ, Crespo-Carbone SM, Foleno BD, Wira E, Wenping H, Morrow B. MexXY expression in Pseudomomas aeruginosa (PsA) and susceptibility to cephalosporins, including ceftobiprole. Presented as a poster at the 48th interscience conference on antimicrobial agents and chemotherapy/infectious diseases society of America 46th annual meeting, Washington, DC, October 25-28, 2008.
46. Queenan AM, Shang W, Crespo-Carbone S, Baum EZ, Bush K. Mechanisms of ceftobiprole and ceftazidime resistance development in gram-negative clinical isolates from cSSSI subjects. Presented as a poster at the 48th interscience conference on antimicrobial agents and chemotherapy/infectious diseases society of America 46th annual meeting, Washington, DC, October 25-28, 2008.
47. Eagle H. A Paradoxical zone phenomenon in the bactericidal action of penicillin in vitro.Science 1948;107:44-5.
48. Deshpande LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect 2003;9:1120-4.
49. Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004;48:2576-80.
50. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008;47:21-33.
51. Chambers HF. Ceftobiprole: in vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect 2006;12(suppl 2):17-22.
52. Schmitt-Hoffmann AH, Roos B, Heep M, et al. Influence of gender on the pharmacokinetics of BAL-9141 after intravenous infusion of pro-drug BAL-5788. Presented as a poster at the 14th European congress of clinical microbiology and infectious diseases, Prague, Czech Republic, May 1-4, 2004.
53. Schmitt-Hoffmann A, Nyman L, Roos B, et al. Dose adjustment in subjects with normal and impaired renal function based on the pharmacokinetics of BAL-5788. Presented as a poster at the 14th European congress of clinical microbiology and infectious diseases, Prague, Czech Republic, May 1-4, 2004.
54. Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn Microbiol Infect Dis 2008;61:96-102.
55. Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 2004;48:1713-18.
56. Lodise TP Jr, Pypstra R, Kahn JB, et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007;51:2378-87.
57. Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftobiprole against 12 gram-positive organisms. Antimicrob Agents Chemother 2006;50:3956-8.
58. Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother 2008;52:3492-6.
59. Leonard SN, Cheung CM, Rybak MJ. Evaluation of the activity of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated (CA-MRSA) and hospital-associated (HA-MRSA) methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2974-6.
60. Hilliard JJ, Foleno B, Wira E, Melton J, Flamm RK, Bush K. Effects of ceftobiprole and vancomycin combinations in vitro and in vivo against Staphylococcus aureus. Presented as a poster at the 48th interscience conference on antimicrobial agents and chemotherapy/infectious diseases society of America 46th annual meeting, Washington, DC, October 25-28, 2008.
61. Arias CA, Singh KV, Panesso D, Murray BE. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including β-lactamase-producing and vancomycin-resistant isolates. Antimicrob Agents Chemother 2007;51:2043-7.
62. Louie A, Fregeau C, Liu W, Bush K, Noel G, Drusano GL. Ceftobiprole and levofloxacin are synergistic against an isolate of Pseudomonas aeruginosa as evaluated in a neutropenic mouse thigh infection model. Presented at the 18th European congress of clinical microbiology and infectious diseases, Barcelona, Spain, April 19-22, 2008.
63. Kresken M, Heep M. In vitro activity of ceftobiprole in combination with ciprofloxacin, levofloxacin, amikacin, and tobramycin against clinical isolates of Pseudomonas aeruginosa. Presented as a poster at the 45th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, December 16-19, 2005.
64. Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother 2002;46:171-7.
65. Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:1618-22.
66. Rouse MS, Hein MM, Anguita-Alonso P, Steckelberg JM, Patel R. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae , Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn Microbiol Infect Dis 2006;55:333-6.
67. Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob Agents Chemother 2008;52:2389-94.
68. Cottagnoud M, Acosta F, Stucki A, Gerber P, Cottagnoud P. Ceftobiprole is superior to cefepime against a Klebsiella pneumoniae strain in experimental meningitides. Presented as a poster at the 18th European congress of clinical microbiology and infectious diseases, Barcelona, Spain, April 19-22, 2008.
69. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44.
70. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55.
71. Nicholson SC, Strauss RS, Michiels B, Noel GJ. Efficacy of ceftobiprole compared to ceftriaxone ± linezolid for the treatment of subjects hospitalized with community-acquired pneumoniae. Presented at the international conference of the American Thoracic Society, Toronto, Ontario, Canada, May 16-21, 2008.
72. Noel GJ, Strauss RS, Shah A, Bagchi P, for the BAP00248/307 Study Group. Ceftobiprole versus ceftazidime combined with linezolid for the treatment of patients with nosocomial pneumonia. Presented as a poster at the 48th interscience conference on antimicrobial agents and chemotherapy/infectious diseases society of America 46th annual meeting, Washington, DC, October 25-28, 2008.
73. National Institutes of Health. Clinical trials for ceftobiprole. Available from http://clinicaltrials.gov/ct2/results?term=ceftobiprole. Accessed July 9, 2008.
74. Deresinski SC. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagn Microbiol Infect Dis 2008;61:103-9.
75. Balis D, Strauss R, Murthy B, Tiian H, Noel GJ. QT/QTc assessment of ceftobiprole in a single-dose study. Presented as a poster at the 17th European congress of clinical microbiology and infectious diseases, Munich, Germany, March 31-April 2, 2007.
76. Chan P, Bishop A, Kupiec TC, et al. Compatibility of ceftobiprole medocaril with selected drugs during simulated Ysite administration. Am J Health Syst Pharm 2008;65:1545-51.